VIR — Vir Biotechnology, Inc.

Is VIR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Vir Biotechnology, Inc. (VIR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.25. The rating moved from Overbought to Oversold on November 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Vir Biotechnology is a small-cap, pipeline-centric biotech whose valuation is driven primarily by clinical milestones and potential partnerships. Financial flexibility and a steady cadence of positive data or deal activity are necessary to support upside; absent those, the stock is vulnerable to funding dilution and adverse readouts. The current market environment is consolidative with flows favoring large-cap pharma, reducing near-term tailwinds for smaller biotech names. Watch upcoming program readouts, partnership announcements and quarterly cash runway disclosures as primary determinants of the stock’s trajectory over the next 1–3 months.

Key factors

  • Pipeline-driven valuation: company value is heavily tied to clinical program progress and upcoming readouts or partnering opportunities.
  • Limited commercial revenue and dependence on external funding or partnerships to sustain R&D and operations.
  • Sector backdrop favors large-cap, diversified pharma which reduces defensive flows into smaller biotech names and may constrain investor demand for VIR.
  • Potential catalysts from trial milestones, licensing deals or collaboration announcements that could re-rate the stock if positive.
  • Measured market tone and low volatility limit near-term momentum; investors appear to be consolidating positions ahead of broader earnings and data flow.

Risks

  • Clinical trial setbacks or negative readouts that would materially reduce future revenue prospects and investor confidence.
  • Cash runway and financing risk leading to dilution if capital markets are unfriendly or partnership/licensing deals are delayed.
  • Competitive pressure from larger, better-capitalized pharma and biotech peers developing similar therapeutics.
  • Regulatory risk and reimbursement uncertainty for novel therapeutics that could affect commercialization economics.
  • Low social sentiment / limited retail momentum and thin trading liquidity that can amplify price moves on news.

See today's live rating, score and targets

Members see the live hourly rating for VIR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.